BenevolentAI
a year of solid progress and growth for enhanced the benevolent platform progressed our pipeline and delivered in commercial collaboration with ben completed phase study and expect top line data in ben submitted in expect to initiate a phase i clinical trial in ben declared as a clinical candidate in with preparation for enabling studies ongoing portfolio into new disease areas year collaboration expansion with additional novel targets selected for in house assets transitioned into lead new in house drug programmes generated using the benevolent platform approval of covid treatment by | BenevolentAI
Company
Deck Type
Deck date
March 2023
Slide
4 of 38
Related slides by other companies
Investor Presentation
August 2023
Investor Conference
January 2024
Investor Presentation
May 2023
Results
March 2023
Other recent decks by BenevolentAI
Results
March 2024
Investor Conference
January 2024
Investor Presentation
May 2023
Investor Conference
January 2023
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2023 Slidebook.io